Vanda falls as US FDA extends review of motion sickness drug

Vanda Pharmaceuticals

28/11/2025 12:43

** Shares of drugmaker Vanda Pharmaceuticals VNDA.O fall 1.1% at $5.14 premarket

** Co says U.S. FDA has requested an extension to complete their review of a partial hold on long-term studies of its experimental motion sickness drug, tradipitant

** VNDA says U.S. FDA will now finish its expedited re-examination of the restrictions by December 5, 2025, instead of the original November 26 deadline

** FDA has started labeling discussions for tradipitant "New Drug Application"; PDUFA action date stays at Dec. 30 - VNDA

** Up to last close, stock up ~11% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))